#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Association	_
1-2	12-14	of	_
1-3	15-24	polygenic	_
1-4	25-29	risk	_
1-5	30-33	for	_
1-6	34-39	major	_
1-7	40-51	psychiatric	_
1-8	52-59	illness	_
1-9	60-64	with	_
1-10	65-76	subcortical	_
1-11	77-84	volumes	_
1-12	85-88	and	_
1-13	89-94	white	_
1-14	95-101	matter	_
1-15	102-111	integrity	_
1-16	112-114	in	_
1-17	115-117	UK	_
1-18	118-125	Biobank	_
1-19	126-131	Major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-20	132-142	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-21	143-151	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-22	152-153	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-23	154-157	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-24	158-159	)	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-25	160-161	,	_
1-26	162-175	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-27	176-177	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-28	178-181	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-29	182-183	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	184-187	and	_
1-31	188-195	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-32	196-204	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-33	205-206	(	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-34	207-209	BP	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-35	210-211	)	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-36	212-215	are	_
1-37	216-222	common	_
1-38	223-224	,	_
1-39	225-234	disabling	_
1-40	235-238	and	_
1-41	239-248	heritable	_
1-42	249-260	psychiatric	_
1-43	261-269	diseases	_
1-44	270-274	with	_
1-45	275-276	a	_
1-46	277-284	complex	_
1-47	285-296	overlapping	_
1-48	297-306	polygenic	_
1-49	307-319	architecture	_
1-50	320-321	.	_

2-1	322-333	Individuals	_
2-2	334-338	with	_
2-3	339-344	these	_
2-4	345-354	disorders	_
2-5	355-356	,	_
2-6	357-359	as	_
2-7	360-364	well	_
2-8	365-367	as	_
2-9	368-373	their	_
2-10	374-384	unaffected	_
2-11	385-394	relatives	_
2-12	395-396	,	_
2-13	397-401	show	_
2-14	402-412	widespread	_
2-15	413-423	structural	_
2-16	424-435	differences	_
2-17	436-438	in	_
2-18	439-454	corticostriatal	_
2-19	455-458	and	_
2-20	459-465	limbic	_
2-21	466-474	networks	_
2-22	475-476	.	_

3-1	477-487	Structural	_
3-2	488-497	variation	_
3-3	498-500	in	_
3-4	501-505	many	_
3-5	506-508	of	_
3-6	509-514	these	_
3-7	515-520	brain	_
3-8	521-528	regions	_
3-9	529-531	is	_
3-10	532-536	also	_
3-11	537-546	heritable	_
3-12	547-550	and	_
3-13	551-560	polygenic	_
3-14	561-564	but	_
3-15	565-572	whether	_
3-16	573-578	their	_
3-17	579-586	genetic	_
3-18	587-599	architecture	_
3-19	600-608	overlaps	_
3-20	609-613	with	_
3-21	614-618	that	_
3-22	619-621	of	_
3-23	622-627	major	_
3-24	628-639	psychiatric	_
3-25	640-649	disorders	_
3-26	650-652	is	_
3-27	653-660	unknown	_
3-28	661-662	.	_

4-1	663-665	We	_
4-2	666-672	sought	_
4-3	673-675	to	_
4-4	676-683	address	_
4-5	684-688	this	_
4-6	689-694	issue	_
4-7	695-697	by	_
4-8	698-707	examining	_
4-9	708-711	the	_
4-10	712-718	impact	_
4-11	719-721	of	_
4-12	722-731	polygenic	_
4-13	732-736	risk	_
4-14	737-739	of	_
4-15	740-743	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-16	744-745	,	_
4-17	746-749	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-18	750-751	,	_
4-19	752-755	and	_
4-20	756-758	BP	_
4-21	759-761	on	_
4-22	762-773	subcortical	_
4-23	774-779	brain	_
4-24	780-787	volumes	_
4-25	788-791	and	_
4-26	792-797	white	_
4-27	798-804	matter	_
4-28	805-806	(	_
4-29	807-809	WM	_
4-30	810-811	)	_
4-31	812-826	microstructure	_
4-32	827-829	in	_
4-33	830-831	a	_
4-34	832-837	large	_
4-35	838-844	single	_
4-36	845-851	sample	_
4-37	852-854	of	_
4-38	855-867	neuroimaging	_
4-39	868-872	data	_
4-40	873-874	;	_
4-41	875-878	the	_
4-42	879-881	UK	_
4-43	882-889	Biobank	_
4-44	890-897	Imaging	_
4-45	898-903	study	_
4-46	904-905	.	_

5-1	906-909	The	_
5-2	910-915	first	_
5-3	916-923	release	_
5-4	924-926	of	_
5-5	927-929	UK	_
5-6	930-937	Biobank	_
5-7	938-945	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
5-8	946-950	data	_
5-9	951-960	comprised	_
5-10	961-973	participants	_
5-11	974-978	with	_
5-12	979-990	overlapping	_
5-13	991-998	genetic	_
5-14	999-1003	data	_
5-15	1004-1007	and	_
5-16	1008-1019	subcortical	_
5-17	1020-1027	volumes	_
5-18	1028-1029	(	_
5-19	1030-1031	N	_
5-20	1032-1033	=	_
5-21	1034-1037	978	_
5-22	1038-1039	)	_
5-23	1040-1043	and	_
5-24	1044-1046	WM	_
5-25	1047-1055	measures	_
5-26	1056-1057	(	_
5-27	1058-1059	N	_
5-28	1060-1061	=	_
5-29	1062-1065	816	_
5-30	1066-1067	)	_
5-31	1068-1069	.	_

6-1	1070-1073	The	_
6-2	1074-1085	calculation	_
6-3	1086-1088	of	_
6-4	1089-1098	polygenic	_
6-5	1099-1103	risk	_
6-6	1104-1110	scores	_
6-7	1111-1114	was	_
6-8	1115-1120	based	_
6-9	1121-1123	on	_
6-10	1124-1135	genome-wide	_
6-11	1136-1147	association	_
6-12	1148-1153	study	_
6-13	1154-1161	results	_
6-14	1162-1171	generated	_
6-15	1172-1174	by	_
6-16	1175-1178	the	_
6-17	1179-1190	Psychiatric	_
6-18	1191-1199	Genomics	_
6-19	1200-1210	Consortium	_
6-20	1211-1212	.	_

7-1	1213-1216	Our	_
7-2	1217-1225	findings	_
7-3	1226-1235	indicated	_
7-4	1236-1238	no	_
7-5	1239-1252	statistically	_
7-6	1253-1264	significant	_
7-7	1265-1277	associations	_
7-8	1278-1285	between	_
7-9	1286-1292	either	_
7-10	1293-1304	subcortical	_
7-11	1305-1312	volumes	_
7-12	1313-1315	or	_
7-13	1316-1318	WM	_
7-14	1319-1333	microstructure	_
7-15	1334-1335	,	_
7-16	1336-1339	and	_
7-17	1340-1349	polygenic	_
7-18	1350-1354	risk	_
7-19	1355-1358	for	_
7-20	1359-1362	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
7-21	1363-1364	,	_
7-22	1365-1368	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-23	1369-1371	or	_
7-24	1372-1374	BP	_
7-25	1375-1376	.	_

8-1	1377-1382	These	_
8-2	1383-1391	findings	_
8-3	1392-1399	suggest	_
8-4	1400-1404	that	_
8-5	1405-1416	subcortical	_
8-6	1417-1422	brain	_
8-7	1423-1430	volumes	_
8-8	1431-1434	and	_
8-9	1435-1437	WM	_
8-10	1438-1452	microstructure	_
8-11	1453-1456	may	_
8-12	1457-1460	not	_
8-13	1461-1463	be	_
8-14	1464-1471	closely	_
8-15	1472-1478	linked	_
8-16	1479-1481	to	_
8-17	1482-1485	the	_
8-18	1486-1493	genetic	_
8-19	1494-1504	mechanisms	_
8-20	1505-1507	of	_
8-21	1508-1513	major	_
8-22	1514-1525	psychiatric	_
8-23	1526-1535	disorders	_
8-24	1536-1537	.	_

9-1	1538-1545	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	1546-1551	Study	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	1552-1562	population	_
9-4	1563-1566	The	_
9-5	1567-1572	first	_
9-6	1573-1580	release	_
9-7	1581-1583	of	_
9-8	1584-1586	UK	_
9-9	1587-1594	Biobank	_
9-10	1595-1602	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
9-11	1603-1607	data	_
9-12	1608-1617	consisted	_
9-13	1618-1620	of	_
9-14	1621-1626	4,446	_
9-15	1627-1635	subjects	_
9-16	1636-1637	(	_
9-17	1638-1653	Nfemales/Nmales	_
9-18	1654-1655	=	_
9-19	1656-1667	2,342/2,104	_
9-20	1668-1669	;	_
9-21	1670-1674	mean	_
9-22	1675-1678	age	_
9-23	1679-1680	±	_
9-24	1681-1684	s.d	_
9-25	1685-1686	.	_

10-1	1687-1688	=	_
10-2	1689-1694	55.52	_
10-3	1695-1696	±	_
10-4	1697-1701	7.62	_
10-5	1702-1707	years	_
10-6	1708-1709	;	_
10-7	1710-1713	age	_
10-8	1714-1719	range	_
10-9	1720-1721	=	_
10-10	1722-1727	40–70	_
10-11	1728-1733	years	_
10-12	1734-1735	)	_
10-13	1736-1740	with	_
10-14	1741-1756	quality-checked	_
10-15	1757-1767	volumetric	_
10-16	1768-1771	and	_
10-17	1772-1775	DTI	_
10-18	1776-1780	data	_
10-19	1781-1784	for	_
10-20	1785-1788	the	_
10-21	1789-1797	analysis	_
10-22	1798-1799	(	_
10-23	1800-1809	conducted	_
10-24	1810-1812	by	_
10-25	1813-1815	UK	_
10-26	1816-1823	Biobank	_
10-27	1824-1825	,	_
10-28	1826-1831	Brain	_
10-29	1832-1839	Imaging	_
10-30	1840-1853	Documentation	_
10-31	1854-1858	V1.1	_
10-32	1859-1860	,	_
10-33	1861-1865	http	_
10-34	1866-1867	:	_
10-35	1868-1889	//www.ukbiobank.ac.uk	_
10-36	1890-1891	)	_
10-37	1892-1893	.	_

11-1	1894-1896	In	_
11-2	1897-1900	the	_
11-3	1901-1908	current	_
11-4	1909-1914	study	_
11-5	1915-1916	,	_
11-6	1917-1925	subjects	_
11-7	1926-1930	were	_
11-8	1931-1939	excluded	_
11-9	1940-1942	if	_
11-10	1943-1947	they	_
11-11	1948-1951	did	_
11-12	1952-1955	not	_
11-13	1956-1963	provide	_
11-14	1964-1971	genetic	_
11-15	1972-1976	data	_
11-16	1977-1978	,	_
11-17	1979-1981	or	_
11-18	1982-1984	if	_
11-19	1985-1989	they	_
11-20	1990-1994	were	_
11-21	1995-2000	known	_
11-22	2001-2003	to	_
11-23	2004-2008	have	_
11-24	2009-2021	participated	_
11-25	2022-2024	in	_
11-26	2025-2032	studies	_
11-27	2033-2037	from	_
11-28	2038-2041	the	_
11-29	2042-2053	Psychiatric	_
11-30	2054-2062	Genomics	_
11-31	2063-2073	Consortium	_
11-32	2074-2075	(	_
11-33	2076-2079	PGC	_
11-34	2080-2081	)	_
11-35	2082-2086	GWAS	_
11-36	2087-2094	dataset	_
11-37	2095-2097	as	_
11-38	2098-2102	this	_
11-39	2103-2106	was	_
11-40	2107-2111	used	_
11-41	2112-2114	to	_
11-42	2115-2124	construct	_
11-43	2125-2128	the	_
11-44	2129-2138	polygenic	_
11-45	2139-2143	risk	_
11-46	2144-2150	scores	_
11-47	2151-2152	(	_
11-48	2153-2157	PGRS	_
11-49	2158-2159	)	_
11-50	2160-2161	.	_

12-1	2162-2164	In	_
12-2	2165-2170	total	_
12-3	2171-2172	,	_
12-4	2173-2176	the	_
12-5	2177-2187	volumetric	_
12-6	2188-2196	analysis	_
12-7	2197-2205	included	_
12-8	2206-2209	978	_
12-9	2210-2218	subjects	_
12-10	2219-2220	(	_
12-11	2221-2236	Nfemales/Nmales	_
12-12	2237-2238	=	_
12-13	2239-2246	499/479	_
12-14	2247-2248	;	_
12-15	2249-2253	mean	_
12-16	2254-2257	age	_
12-17	2258-2259	±	_
12-18	2260-2263	s.d	_
12-19	2264-2265	.	_

13-1	2266-2267	=	_
13-2	2268-2273	55.32	_
13-3	2274-2275	±	_
13-4	2276-2280	7.38	_
13-5	2281-2286	years	_
13-6	2287-2288	;	_
13-7	2289-2292	age	_
13-8	2293-2298	range	_
13-9	2299-2300	=	_
13-10	2301-2306	40–70	_
13-11	2307-2312	years	_
13-12	2313-2314	)	_
13-13	2315-2318	and	_
13-14	2319-2322	the	_
13-15	2323-2326	DTI	_
13-16	2327-2335	analysis	_
13-17	2336-2344	included	_
13-18	2345-2348	816	_
13-19	2349-2357	subjects	_
13-20	2358-2359	(	_
13-21	2360-2375	Nfemales/Nmales	_
13-22	2376-2377	=	_
13-23	2378-2385	413/403	_
13-24	2386-2387	;	_
13-25	2388-2392	mean	_
13-26	2393-2396	age	_
13-27	2397-2398	±	_
13-28	2399-2402	s.d	_
13-29	2403-2404	.	_

14-1	2405-2406	=	_
14-2	2407-2412	55.49	_
14-3	2413-2414	±	_
14-4	2415-2419	7.26	_
14-5	2420-2425	years	_
14-6	2426-2427	;	_
14-7	2428-2431	age	_
14-8	2432-2437	range	_
14-9	2438-2439	=	_
14-10	2440-2445	40–70	_
14-11	2446-2451	years	_
14-12	2452-2453	)	_
14-13	2454-2455	.	_

15-1	2456-2462	Sample	_
15-2	2463-2470	overlap	_
15-3	2471-2472	(	_
15-4	2473-2484	individuals	_
15-5	2485-2493	included	_
15-6	2494-2496	in	_
15-7	2497-2501	both	_
15-8	2502-2505	the	_
15-9	2506-2509	DTI	_
15-10	2510-2513	and	_
15-11	2514-2524	volumetric	_
15-12	2525-2533	analysis	_
15-13	2534-2535	)	_
15-14	2536-2544	included	_
15-15	2545-2546	N	_
15-16	2547-2548	=	_
15-17	2549-2552	816	_
15-18	2553-2565	participants	_
15-19	2566-2569	and	_
15-20	2570-2573	the	_
15-21	2574-2584	volumetric	_
15-22	2585-2593	analysis	_
15-23	2594-2602	included	_
15-24	2603-2604	N	_
15-25	2605-2606	=	_
15-26	2607-2610	162	_
15-27	2611-2616	extra	_
15-28	2617-2629	participants	_
15-29	2630-2631	.	_

16-1	2632-2634	In	_
16-2	2635-2643	addition	_
16-3	2644-2645	,	_
16-4	2646-2647	a	_
16-5	2648-2659	sensitivity	_
16-6	2660-2668	analysis	_
16-7	2669-2672	was	_
16-8	2673-2682	performed	_
16-9	2683-2688	where	_
16-10	2689-2691	we	_
16-11	2692-2699	imposed	_
16-12	2700-2708	internal	_
16-13	2709-2716	imaging	_
16-14	2717-2724	quality	_
16-15	2725-2731	checks	_
16-16	2732-2733	,	_
16-17	2734-2743	excluding	_
16-18	2744-2755	individuals	_
16-19	2756-2761	whose	_
16-20	2762-2773	subcortical	_
16-21	2774-2780	volume	_
16-22	2781-2783	or	_
16-23	2784-2786	FA	_
16-24	2787-2793	values	_
16-25	2794-2798	were	_
16-26	2799-2806	greater	_
16-27	2807-2811	than	_
16-28	2812-2817	three	_
16-29	2818-2826	standard	_
16-30	2827-2837	deviations	_
16-31	2838-2843	above	_
16-32	2844-2846	or	_
16-33	2847-2852	below	_
16-34	2853-2856	the	_
16-35	2857-2861	mean	_
16-36	2862-2865	for	_
16-37	2866-2870	that	_
16-38	2871-2878	measure	_
16-39	2879-2880	.	_

17-1	2881-2884	The	_
17-2	2885-2896	sensitivity	_
17-3	2897-2905	analysis	_
17-4	2906-2907	,	_
17-5	2908-2915	further	_
17-6	2916-2924	referred	_
17-7	2925-2927	to	_
17-8	2928-2930	as	_
17-9	2931-2934	the	_
17-10	2935-2941	sample	_
17-11	2942-2951	excluding	_
17-12	2952-2960	outliers	_
17-13	2961-2962	,	_
17-14	2963-2971	included	_
17-15	2972-2975	892	_
17-16	2976-2977	(	_
17-17	2978-2987	exclusion	_
17-18	2988-2990	of	_
17-19	2991-2993	86	_
17-20	2994-3002	subjects	_
17-21	3003-3004	;	_
17-22	3005-3020	Nfemales/Nmales	_
17-23	3021-3022	=	_
17-24	3023-3030	477/415	_
17-25	3031-3032	;	_
17-26	3033-3037	mean	_
17-27	3038-3041	age	_
17-28	3042-3043	±	_
17-29	3044-3047	s.d	_
17-30	3048-3049	.	_

18-1	3050-3051	=	_
18-2	3052-3057	55.29	_
18-3	3058-3059	±	_
18-4	3060-3064	7.31	_
18-5	3065-3070	years	_
18-6	3071-3072	;	_
18-7	3073-3076	age	_
18-8	3077-3082	range	_
18-9	3083-3084	=	_
18-10	3085-3090	40–70	_
18-11	3091-3096	years	_
18-12	3097-3098	)	_
18-13	3099-3102	and	_
18-14	3103-3106	733	_
18-15	3107-3108	(	_
18-16	3109-3118	exclusion	_
18-17	3119-3121	of	_
18-18	3122-3124	83	_
18-19	3125-3132	subjecs	_
18-20	3133-3134	;	_
18-21	3135-3150	Nfemales/Nmales	_
18-22	3151-3152	=	_
18-23	3153-3160	373/360	_
18-24	3161-3162	;	_
18-25	3163-3167	mean	_
18-26	3168-3171	age	_
18-27	3172-3173	±	_
18-28	3174-3177	s.d	_
18-29	3178-3179	.	_

19-1	3180-3181	=	_
19-2	3182-3187	55.31	_
19-3	3188-3189	±	_
19-4	3190-3194	7.22	_
19-5	3195-3200	years	_
19-6	3201-3202	;	_
19-7	3203-3206	age	_
19-8	3207-3212	range	_
19-9	3213-3214	=	_
19-10	3215-3220	40–70	_
19-11	3221-3226	years	_
19-12	3227-3228	)	_
19-13	3229-3237	subjects	_
19-14	3238-3241	for	_
19-15	3242-3245	the	_
19-16	3246-3256	volumetric	_
19-17	3257-3260	and	_
19-18	3261-3264	DTI	_
19-19	3265-3273	analysis	_
19-20	3274-3286	respectively	_
19-21	3287-3288	.	_

20-1	3289-3295	Sample	_
20-2	3296-3303	overlap	_
20-3	3304-3307	for	_
20-4	3308-3311	the	_
20-5	3312-3318	sample	_
20-6	3319-3328	excluding	_
20-7	3329-3337	outliers	_
20-8	3338-3346	included	_
20-9	3347-3348	N	_
20-10	3349-3350	=	_
20-11	3351-3354	679	_
20-12	3355-3356	,	_
20-13	3357-3360	and	_
20-14	3361-3364	the	_
20-15	3365-3375	volumetric	_
20-16	3376-3384	analysis	_
20-17	3385-3393	included	_
20-18	3394-3397	213	_
20-19	3398-3404	unique	_
20-20	3405-3417	observations	_
20-21	3418-3419	,	_
20-22	3420-3427	whereas	_
20-23	3428-3431	the	_
20-24	3432-3435	DTI	_
20-25	3436-3444	analysis	_
20-26	3445-3453	included	_
20-27	3454-3456	54	_
20-28	3457-3463	unique	_
20-29	3464-3476	observations	_
20-30	3477-3478	.	_

21-1	3479-3483	This	_
21-2	3484-3489	study	_
21-3	3490-3493	has	_
21-4	3494-3498	been	_
21-5	3499-3507	approved	_
21-6	3508-3510	by	_
21-7	3511-3514	the	_
21-8	3515-3523	National	_
21-9	3524-3530	Health	_
21-10	3531-3538	Service	_
21-11	3539-3540	(	_
21-12	3541-3544	NHS	_
21-13	3545-3546	)	_
21-14	3547-3555	Research	_
21-15	3556-3562	Ethics	_
21-16	3563-3570	Service	_
21-17	3571-3572	(	_
21-18	3573-3581	approval	_
21-19	3582-3588	letter	_
21-20	3589-3594	dated	_
21-21	3595-3599	17th	_
21-22	3600-3604	June	_
21-23	3605-3609	2011	_
21-24	3610-3611	,	_
21-25	3612-3621	reference	_
21-26	3622-3623	:	_
21-27	3624-3634	11/NW/0382	_
21-28	3635-3636	)	_
21-29	3637-3638	,	_
21-30	3639-3642	and	_
21-31	3643-3645	by	_
21-32	3646-3649	the	_
21-33	3650-3652	UK	_
21-34	3653-3660	Biobank	_
21-35	3661-3667	Access	_
21-36	3668-3677	Committee	_
21-37	3678-3679	(	_
21-38	3680-3687	Project	_
21-39	3688-3689	#	_
21-40	3690-3694	4844	_
21-41	3695-3696	)	_
21-42	3697-3698	.	_

22-1	3699-3702	All	_
22-2	3703-3714	experiments	_
22-3	3715-3719	were	_
22-4	3720-3729	performed	_
22-5	3730-3732	in	_
22-6	3733-3743	accordance	_
22-7	3744-3748	with	_
22-8	3749-3759	guidelines	_
22-9	3760-3763	and	_
22-10	3764-3775	regulations	_
22-11	3776-3780	from	_
22-12	3781-3786	these	_
22-13	3787-3797	committees	_
22-14	3798-3799	.	_

23-1	3800-3807	Written	_
23-2	3808-3816	informed	_
23-3	3817-3824	consent	_
23-4	3825-3828	was	_
23-5	3829-3837	obtained	_
23-6	3838-3842	from	_
23-7	3843-3847	each	_
23-8	3848-3855	subject	_
23-9	3856-3857	.	_

24-1	3858-3868	Genotyping	_
24-2	3869-3872	and	_
24-3	3873-3883	derivation	_
24-4	3884-3886	of	_
24-5	3887-3896	polygenic	_
24-6	3897-3901	risk	_
24-7	3902-3908	scores	_
24-8	3909-3919	Procedures	_
24-9	3920-3923	for	_
24-10	3924-3927	DNA	_
24-11	3928-3938	collection	_
24-12	3939-3942	and	_
24-13	3943-3953	genotyping	_
24-14	3954-3956	in	_
24-15	3957-3959	UK	_
24-16	3960-3967	Biobank	_
24-17	3968-3972	have	_
24-18	3973-3977	been	_
24-19	3978-3987	described	_
24-20	3988-3998	previously	_
24-21	3999-4001	by	_
24-22	4002-4011	Hagenaars	_
24-23	4012-4014	et	_
24-24	4015-4017	al	_
24-25	4018-4020	..	_

25-1	4021-4029	Subjects	_
25-2	4030-4034	were	_
25-3	4035-4043	excluded	_
25-4	4044-4048	from	_
25-5	4049-4052	the	_
25-6	4053-4057	PGRS	_
25-7	4058-4066	analysis	_
25-8	4067-4069	if	_
25-9	4070-4074	they	_
25-10	4075-4078	had	_
25-11	4079-4080	a	_
25-12	4081-4092	non-British	_
25-13	4093-4101	ancestry	_
25-14	4102-4103	,	_
25-15	4104-4110	gender	_
25-16	4111-4119	mismatch	_
25-17	4120-4121	,	_
25-18	4122-4133	relatedness	_
25-19	4134-4135	(	_
25-20	4136-4137	r	_
25-21	4138-4139	>	_
25-22	4140-4145	0.044	_
25-23	4146-4147	)	_
25-24	4148-4149	,	_
25-25	4150-4153	and	_
25-26	4154-4162	genotype	_
25-27	4163-4174	missingness	_
25-28	4175-4181	bigger	_
25-29	4182-4186	than	_
25-30	4187-4188	2	_
25-31	4189-4190	%	_
25-32	4191-4192	.	_

26-1	4193-4197	PGRS	_
26-2	4198-4201	for	_
26-3	4202-4205	the	_
26-4	4206-4211	three	_
26-5	4212-4218	traits	_
26-6	4219-4221	of	_
26-7	4222-4230	interest	_
26-8	4231-4232	(	_
26-9	4233-4237	i.e.	_
26-10	4238-4239	,	_
26-11	4240-4243	MDD	_
26-12	4244-4245	,	_
26-13	4246-4249	SCZ	_
26-14	4250-4251	,	_
26-15	4252-4254	BP	_
26-16	4255-4256	)	_
26-17	4257-4261	were	_
26-18	4262-4269	created	_
26-19	4270-4275	using	_
26-20	4276-4282	PRSice	_
26-21	4283-4284	.	_

27-1	4285-4288	For	_
27-2	4289-4293	each	_
27-3	4294-4301	subject	_
27-4	4302-4306	PGRS	_
27-5	4307-4311	were	_
27-6	4312-4322	calculated	_
27-7	4323-4325	by	_
27-8	4326-4333	summing	_
27-9	4334-4337	the	_
27-10	4338-4344	number	_
27-11	4345-4347	of	_
27-12	4348-4352	risk	_
27-13	4353-4360	alleles	_
27-14	4361-4369	weighted	_
27-15	4370-4372	by	_
27-16	4373-4376	the	_
27-17	4377-4385	strength	_
27-18	4386-4388	of	_
27-19	4389-4392	its	_
27-20	4393-4404	association	_
27-21	4405-4409	with	_
27-22	4410-4413	the	_
27-23	4414-4419	trait	_
27-24	4420-4422	of	_
27-25	4423-4431	interest	_
27-26	4432-4433	.	_

28-1	4434-4437	The	_
28-2	4438-4446	strength	_
28-3	4447-4449	of	_
28-4	4450-4454	this	_
28-5	4455-4466	association	_
28-6	4467-4470	has	_
28-7	4471-4475	been	_
28-8	4476-4486	calculated	_
28-9	4487-4497	previously	_
28-10	4498-4500	by	_
28-11	4501-4504	the	_
28-12	4505-4508	PGC	_
28-13	4509-4510	(	_
28-14	4511-4515	PGC2	_
28-15	4516-4519	for	_
28-16	4520-4523	SCZ	_
28-17	4524-4525	)	_
28-18	4526-4527	.	_

29-1	4528-4533	Prior	_
29-2	4534-4536	to	_
29-3	4537-4548	calculating	_
29-4	4549-4552	the	_
29-5	4553-4557	PGRS	_
29-6	4558-4559	,	_
29-7	4560-4566	single	_
29-8	4567-4577	nucleotide	_
29-9	4578-4591	polymorphisms	_
29-10	4592-4593	(	_
29-11	4594-4598	SNPs	_
29-12	4599-4600	)	_
29-13	4601-4605	were	_
29-14	4606-4614	excluded	_
29-15	4615-4617	if	_
29-16	4618-4622	they	_
29-17	4623-4626	had	_
29-18	4627-4628	a	_
29-19	4629-4634	minor	_
29-20	4635-4641	allele	_
29-21	4642-4651	frequency	_
29-22	4652-4656	less	_
29-23	4657-4661	than	_
29-24	4662-4663	1	_
29-25	4664-4665	%	_
29-26	4666-4667	,	_
29-27	4668-4676	deviated	_
29-28	4677-4690	significantly	_
29-29	4691-4695	from	_
29-30	4696-4710	Hardy-Weinberg	_
29-31	4711-4722	equilibrium	_
29-32	4723-4724	(	_
29-33	4725-4726	p	_
29-34	4727-4728	<	_
29-35	4729-4730	1	_
29-36	4731-4732	×	_
29-37	4733-4737	10−6	_
29-38	4738-4739	)	_
29-39	4740-4742	in	_
29-40	4743-4746	the	_
29-41	4747-4752	total	_
29-42	4753-4759	sample	_
29-43	4760-4762	of	_
29-44	4763-4770	founder	_
29-45	4771-4782	individuals	_
29-46	4783-4784	,	_
29-47	4785-4787	or	_
29-48	4788-4791	had	_
29-49	4792-4793	a	_
29-50	4794-4798	call	_
29-51	4799-4803	rate	_
29-52	4804-4806	of	_
29-53	4807-4811	less	_
29-54	4812-4816	than	_
29-55	4817-4819	99	_
29-56	4820-4821	%	_
29-57	4822-4823	.	_

30-1	4824-4827	The	_
30-2	4828-4837	remaining	_
30-3	4838-4842	SNPs	_
30-4	4843-4847	were	_
30-5	4848-4852	used	_
30-6	4853-4855	to	_
30-7	4856-4865	calculate	_
30-8	4866-4868	15	_
30-9	4869-4885	multidimensional	_
30-10	4886-4893	scaling	_
30-11	4894-4895	(	_
30-12	4896-4899	MDS	_
30-13	4900-4901	)	_
30-14	4902-4910	ancestry	_
30-15	4911-4921	components	_
30-16	4922-4923	(	_
30-17	4924-4926	to	_
30-18	4927-4934	account	_
30-19	4935-4938	for	_
30-20	4939-4949	population	_
30-21	4950-4959	structure	_
30-22	4960-4961	)	_
30-23	4962-4963	.	_

31-1	4964-4967	For	_
31-2	4968-4971	the	_
31-3	4972-4976	main	_
31-4	4977-4984	results	_
31-5	4985-4986	,	_
31-6	4987-4990	the	_
31-7	4991-4994	SNP	_
31-8	4995-5004	inclusion	_
31-9	5005-5014	threshold	_
31-10	5015-5018	was	_
31-11	5019-5022	set	_
31-12	5023-5025	as	_
31-13	5026-5027	p	_
31-14	5028-5029	≤	_
31-15	5030-5033	0.5	_
31-16	5034-5035	,	_
31-17	5036-5038	as	_
31-18	5039-5046	Purcell	_
31-19	5047-5049	et	_
31-20	5050-5052	al	_
31-21	5053-5054	.	_

32-1	5055-5058	and	_
32-2	5059-5066	studies	_
32-3	5067-5076	following	_
32-4	5077-5081	this	_
32-5	5082-5086	work	_
32-6	5087-5088	,	_
32-7	5089-5093	have	_
32-8	5094-5099	shown	_
32-9	5100-5104	that	_
32-10	5105-5109	this	_
32-11	5110-5119	threshold	_
32-12	5120-5122	is	_
32-13	5123-5132	generally	_
32-14	5133-5136	the	_
32-15	5137-5141	most	_
32-16	5142-5152	predictive	_
32-17	5153-5155	of	_
32-18	5156-5168	case-control	_
32-19	5169-5175	status	_
32-20	5176-5178	in	_
32-21	5179-5189	subsequent	_
32-22	5190-5197	studies	_
32-23	5198-5199	.	_

33-1	5200-5205	Using	_
33-2	5206-5209	the	_
33-3	5210-5211	p	_
33-4	5212-5213	≤	_
33-5	5214-5217	0.5	_
33-6	5218-5221	SNP	_
33-7	5222-5231	inclusion	_
33-8	5232-5241	threshold	_
33-9	5242-5243	,	_
33-10	5244-5251	631,763	_
33-11	5252-5253	,	_
33-12	5254-5263	5,422,836	_
33-13	5264-5267	and	_
33-14	5268-5277	1,283,324	_
33-15	5278-5282	SNPs	_
33-16	5283-5284	(	_
33-17	5285-5290	after	_
33-18	5291-5293	LD	_
33-19	5294-5301	pruning	_
33-20	5302-5303	)	_
33-21	5304-5308	were	_
33-22	5309-5317	included	_
33-23	5318-5321	for	_
33-24	5322-5325	the	_
33-25	5326-5337	calculation	_
33-26	5338-5340	of	_
33-27	5341-5349	MDD-PGRS	_
33-28	5350-5351	,	_
33-29	5352-5360	SCZ-PGRS	_
33-30	5361-5364	and	_
33-31	5365-5372	BP-PGRS	_
33-32	5373-5374	,	_
33-33	5375-5387	respectively	_
33-34	5388-5389	.	_

34-1	5390-5397	Results	_
34-2	5398-5407	generated	_
34-3	5408-5410	by	_
34-4	5411-5412	a	_
34-5	5413-5416	SNP	_
34-6	5417-5426	inclusion	_
34-7	5427-5436	threshold	_
34-8	5437-5439	of	_
34-9	5440-5441	p	_
34-10	5442-5443	≤	_
34-11	5444-5448	0.01	_
34-12	5449-5450	,	_
34-13	5451-5452	p	_
34-14	5453-5454	≤	_
34-15	5455-5459	0.05	_
34-16	5460-5461	,	_
34-17	5462-5463	p	_
34-18	5464-5465	≤	_
34-19	5466-5469	0.1	_
34-20	5470-5473	and	_
34-21	5474-5475	p	_
34-22	5476-5477	≤	_
34-23	5478-5481	1.0	_
34-24	5482-5485	are	_
34-25	5486-5494	reported	_
34-26	5495-5497	in	_
34-27	5498-5511	supplementary	_
34-28	5512-5521	materials	_
34-29	5522-5523	.	_

35-1	5524-5529	Image	_
35-2	5530-5541	acquisition	_
35-3	5542-5545	and	_
35-4	5546-5558	Neuroimaging	_
35-5	5559-5563	data	_
35-6	5564-5578	pre-processing	_
35-7	5579-5589	Procedures	_
35-8	5590-5593	for	_
35-9	5594-5599	image	_
35-10	5600-5611	acquisition	_
35-11	5612-5615	and	_
35-12	5616-5630	pre-processing	_
35-13	5631-5635	have	_
35-14	5636-5640	been	_
35-15	5641-5650	performed	_
35-16	5651-5653	by	_
35-17	5654-5656	UK	_
35-18	5657-5664	Biobank	_
35-19	5665-5666	,	_
35-20	5667-5670	and	_
35-21	5671-5674	are	_
35-22	5675-5684	available	_
35-23	5685-5687	on	_
35-24	5688-5691	the	_
35-25	5692-5694	UK	_
35-26	5695-5702	Biobank	_
35-27	5703-5710	website	_
35-28	5711-5712	(	_
35-29	5713-5717	http	_
35-30	5718-5719	:	_
35-31	5720-5742	//www.ukbiobank.ac.uk/	_
35-32	5743-5744	)	_
35-33	5745-5746	,	_
35-34	5747-5750	and	_
35-35	5751-5755	have	_
35-36	5756-5760	been	_
35-37	5761-5771	documented	_
35-38	5772-5782	previously	_
35-39	5783-5784	.	_

36-1	5785-5787	In	_
36-2	5788-5793	short	_
36-3	5794-5795	,	_
36-4	5796-5802	images	_
36-5	5803-5807	were	_
36-6	5808-5817	collected	_
36-7	5818-5820	in	_
36-8	5821-5828	Cheadle	_
36-9	5829-5839	Manchester	_
36-10	5840-5842	on	_
36-11	5843-5844	a	_
36-12	5845-5852	Siemens	_
36-13	5853-5858	Skyra	_
36-14	5859-5862	3.0	_
36-15	5863-5864	T	_
36-16	5865-5872	scanner	_
36-17	5873-5874	(	_
36-18	5875-5882	Siemens	_
36-19	5883-5890	Medical	_
36-20	5891-5900	Solutions	_
36-21	5901-5902	,	_
36-22	5903-5910	Germany	_
36-23	5911-5912	)	_
36-24	5913-5917	with	_
36-25	5918-5919	a	_
36-26	5920-5930	32-channel	_
36-27	5931-5935	head	_
36-28	5936-5940	coil	_
36-29	5941-5942	(	_
36-30	5943-5948	https	_
36-31	5949-5950	:	_
36-32	5951-6006	//www.healthcare.siemens.com/magnetic-resonance-imaging	_
36-33	6007-6008	)	_
36-34	6009-6010	.	_

37-1	6011-6022	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-2	6023-6028	scans	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-3	6029-6033	were	_
37-4	6034-6042	acquired	_
37-5	6043-6048	using	_
37-6	6049-6050	a	_
37-7	6051-6053	3D	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
37-8	6054-6060	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
37-9	6061-6062	(	_
37-10	6063-6073	resolution	_
37-11	6074-6075	1	_
37-12	6076-6079	mm3	_
37-13	6080-6089	isotropic	_
37-14	6090-6096	voxels	_
37-15	6097-6098	)	_
37-16	6099-6107	sequence	_
37-17	6108-6109	,	_
37-18	6110-6113	and	_
37-19	6114-6132	diffusion-weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
37-20	6133-6134	(	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
37-21	6135-6137	DW	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
37-22	6138-6139	)	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
37-23	6140-6145	scans	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
37-24	6146-6150	were	_
37-25	6151-6159	acquired	_
37-26	6160-6164	with	_
37-27	6165-6166	a	_
37-28	6167-6176	monopolar	_
37-29	6177-6193	Steejskal-Tanner	_
37-30	6194-6199	pulse	_
37-31	6200-6208	sequence	_
37-32	6209-6212	and	_
37-33	6213-6224	multi-shell	_
37-34	6225-6236	acquisition	_
37-35	6237-6238	(	_
37-36	6239-6241	b0	_
37-37	6242-6243	=	_
37-38	6244-6245	0	_
37-39	6246-6251	s/mm2	_
37-40	6252-6253	,	_
37-41	6254-6255	b	_
37-42	6256-6257	=	_
37-43	6258-6263	1,000	_
37-44	6264-6269	s/mm2	_
37-45	6270-6271	,	_
37-46	6272-6273	b	_
37-47	6274-6275	=	_
37-48	6276-6281	2,000	_
37-49	6282-6287	s/mm2	_
37-50	6288-6289	)	_
37-51	6290-6291	.	_

38-1	6292-6298	Images	_
38-2	6299-6303	were	_
38-3	6304-6316	preprocessed	_
38-4	6317-6320	and	_
38-5	6321-6329	analysed	_
38-6	6330-6334	with	_
38-7	6335-6338	the	_
38-8	6339-6344	FMRIB	_
38-9	6345-6353	Software	_
38-10	6354-6361	Library	_
38-11	6362-6363	(	_
38-12	6364-6367	FSL	_
38-13	6368-6369	)	_
38-14	6370-6371	(	_
38-15	6372-6376	http	_
38-16	6377-6378	:	_
38-17	6379-6403	//fsl.fmrib.ox.ac.uk/fsl	_
38-18	6404-6405	)	_
38-19	6406-6407	.	_

39-1	6408-6412	More	_
39-2	6413-6421	detailed	_
39-3	6422-6433	information	_
39-4	6434-6436	is	_
39-5	6437-6445	reported	_
39-6	6446-6448	in	_
39-7	6449-6452	the	_
39-8	6453-6466	supplementary	_
39-9	6467-6476	materials	_
39-10	6477-6478	.	_

40-1	6479-6490	Statistical	_
40-2	6491-6499	analysis	_
40-3	6500-6503	All	_
40-4	6504-6512	analyses	_
40-5	6513-6517	were	_
40-6	6518-6527	performed	_
40-7	6528-6533	using	_
40-8	6534-6535	R	_
40-9	6536-6537	(	_
40-10	6538-6545	version	_
40-11	6546-6551	3.2.3	_
40-12	6552-6553	)	_
40-13	6554-6556	in	_
40-14	6557-6560	the	_
40-15	6561-6566	Linux	_
40-16	6567-6578	environment	_
40-17	6579-6580	(	_
40-18	6581-6582	R	_
40-19	6583-6594	Development	_
40-20	6595-6599	Core	_
40-21	6600-6604	Team	_
40-22	6605-6606	,	_
40-23	6607-6611	2010	_
40-24	6612-6613	)	_
40-25	6614-6615	.	_

41-1	6616-6618	To	_
41-2	6619-6626	examine	_
41-3	6627-6634	whether	_
41-4	6635-6641	higher	_
41-5	6642-6646	PGRS	_
41-6	6647-6651	were	_
41-7	6652-6662	associated	_
41-8	6663-6667	with	_
41-9	6668-6676	globally	_
41-10	6677-6681	poor	_
41-11	6682-6684	WM	_
41-12	6685-6699	microstructure	_
41-13	6700-6701	,	_
41-14	6702-6709	general	_
41-15	6710-6720	components	_
41-16	6721-6724	for	_
41-17	6725-6727	FA	_
41-18	6728-6729	(	_
41-19	6730-6733	gFA	_
41-20	6734-6735	)	_
41-21	6736-6739	and	_
41-22	6740-6742	MD	_
41-23	6743-6744	(	_
41-24	6745-6748	gMD	_
41-25	6749-6750	)	_
41-26	6751-6757	across	_
41-27	6758-6761	the	_
41-28	6762-6764	27	_
41-29	6765-6767	WM	_
41-30	6768-6774	tracts	_
41-31	6775-6779	were	_
41-32	6780-6790	calculated	_
41-33	6791-6792	.	_

42-1	6793-6799	Latent	_
42-2	6800-6808	measures	_
42-3	6809-6810	,	_
42-4	6811-6821	explaining	_
42-5	6822-6823	a	_
42-6	6824-6831	portion	_
42-7	6832-6834	of	_
42-8	6835-6843	variance	_
42-9	6844-6846	WM	_
42-10	6847-6856	structure	_
42-11	6857-6858	,	_
42-12	6859-6863	were	_
42-13	6864-6874	calculated	_
42-14	6875-6878	for	_
42-15	6879-6883	both	_
42-16	6884-6886	FA	_
42-17	6887-6890	and	_
42-18	6891-6893	MD	_
42-19	6894-6896	by	_
42-20	6897-6907	extracting	_
42-21	6908-6911	the	_
42-22	6912-6918	scores	_
42-23	6919-6921	on	_
42-24	6922-6925	the	_
42-25	6926-6931	first	_
42-26	6932-6941	unrotated	_
42-27	6942-6952	components	_
42-28	6953-6954	,	_
42-29	6955-6960	using	_
42-30	6961-6962	a	_
42-31	6963-6972	principal	_
42-32	6973-6982	component	_
42-33	6983-6991	analysis	_
42-34	6992-6993	(	_
42-35	6994-6997	PCA	_
42-36	6998-6999	)	_
42-37	7000-7002	on	_
42-38	7003-7006	the	_
42-39	7007-7009	27	_
42-40	7010-7012	WM	_
42-41	7013-7019	tracts	_
42-42	7020-7021	.	_

43-1	7022-7025	The	_
43-2	7026-7031	first	_
43-3	7032-7042	components	_
43-4	7043-7052	accounted	_
43-5	7053-7056	for	_
43-6	7057-7058	a	_
43-7	7059-7063	mean	_
43-8	7064-7066	of	_
43-9	7067-7072	44.82	_
43-10	7073-7074	%	_
43-11	7075-7078	and	_
43-12	7079-7084	41.73	_
43-13	7085-7086	%	_
43-14	7087-7089	of	_
43-15	7090-7095	total	_
43-16	7096-7104	variance	_
43-17	7105-7107	in	_
43-18	7108-7110	FA	_
43-19	7111-7114	and	_
43-20	7115-7116	,	_
43-21	7117-7122	47.45	_
43-22	7123-7124	%	_
43-23	7125-7128	and	_
43-24	7129-7134	45.35	_
43-25	7135-7136	%	_
43-26	7137-7139	in	_
43-27	7140-7142	MD	_
43-28	7143-7144	,	_
43-29	7145-7147	in	_
43-30	7148-7151	the	_
43-31	7152-7158	sample	_
43-32	7159-7168	including	_
43-33	7169-7172	and	_
43-34	7173-7182	excluding	_
43-35	7183-7191	outliers	_
43-36	7192-7204	respectively	_
43-37	7205-7206	(	_
43-38	7207-7215	loadings	_
43-39	7216-7218	of	_
43-40	7219-7225	tracts	_
43-41	7226-7228	on	_
43-42	7229-7232	the	_
43-43	7233-7238	first	_
43-44	7239-7245	latent	_
43-45	7246-7255	component	_
43-46	7256-7257	>	_
43-47	7258-7262	0.15	_
43-48	7263-7264	)	_
43-49	7265-7266	.	_

44-1	7267-7269	To	_
44-2	7270-7277	examine	_
44-3	7278-7285	whether	_
44-4	7286-7292	higher	_
44-5	7293-7297	PGRS	_
44-6	7298-7302	were	_
44-7	7303-7314	selectively	_
44-8	7315-7325	associated	_
44-9	7326-7330	with	_
44-10	7331-7335	poor	_
44-11	7336-7338	WM	_
44-12	7339-7348	structure	_
44-13	7349-7351	in	_
44-14	7352-7353	a	_
44-15	7354-7361	certain	_
44-16	7362-7376	classification	_
44-17	7377-7378	,	_
44-18	7379-7383	this	_
44-19	7384-7387	PCA	_
44-20	7388-7391	was	_
44-21	7392-7396	also	_
44-22	7397-7406	performed	_
44-23	7407-7417	separately	_
44-24	7418-7421	for	_
44-25	7422-7428	groups	_
44-26	7429-7431	of	_
44-27	7432-7441	different	_
44-28	7442-7452	categories	_
44-29	7453-7455	of	_
44-30	7456-7458	WM	_
44-31	7459-7465	tracts	_
44-32	7466-7467	,	_
44-33	7468-7477	including	_
44-34	7478-7489	association	_
44-35	7490-7491	(	_
44-36	7492-7500	inferior	_
44-37	7501-7517	fronto-occipital	_
44-38	7518-7528	fasciculus	_
44-39	7529-7530	,	_
44-40	7531-7539	inferior	_
44-41	7540-7552	longitudinal	_
44-42	7553-7563	fasciculus	_
44-43	7564-7565	,	_
44-44	7566-7574	superior	_
44-45	7575-7587	longitudinal	_
44-46	7588-7598	fasciculus	_
44-47	7599-7600	,	_
44-48	7601-7609	uncinate	_
44-49	7610-7620	fasciculus	_
44-50	7621-7622	,	_
44-51	7623-7631	cingulum	_
44-52	7632-7633	)	_
44-53	7634-7635	,	_
44-54	7636-7646	projection	_
44-55	7647-7648	(	_
44-56	7649-7656	forceps	_
44-57	7657-7662	minor	_
44-58	7663-7664	,	_
44-59	7665-7672	forceps	_
44-60	7673-7678	major	_
44-61	7679-7680	,	_
44-62	7681-7694	corticospinal	_
44-63	7695-7701	tracts	_
44-64	7702-7703	,	_
44-65	7704-7712	acoustic	_
44-66	7713-7722	radiation	_
44-67	7723-7724	,	_
44-68	7725-7731	medial	_
44-69	7732-7741	lemniscus	_
44-70	7742-7743	,	_
44-71	7744-7750	middle	_
44-72	7751-7761	cerebellar	_
44-73	7762-7770	peduncle	_
44-74	7771-7772	)	_
44-75	7773-7776	and	_
44-76	7777-7785	thalamic	_
44-77	7786-7795	radiation	_
44-78	7796-7802	fibers	_
44-79	7803-7804	,	_
44-80	7805-7815	separately	_
44-81	7816-7817	(	_
44-82	7818-7824	sample	_
44-83	7825-7834	including	_
44-84	7835-7843	outliers	_
44-85	7844-7845	:	_
44-86	7846-7854	variance	_
44-87	7855-7864	explained	_
44-88	7865-7866	=	_
44-89	7867-7872	54.52	_
44-90	7873-7874	%	_
44-91	7875-7876	,	_
44-92	7877-7882	38.68	_
44-93	7883-7884	%	_
44-94	7885-7888	and	_
44-95	7889-7894	61.92	_
44-96	7895-7896	%	_
44-97	7897-7909	respectively	_
44-98	7910-7913	for	_
44-99	7914-7918	each	_
44-100	7919-7925	subset	_
44-101	7926-7927	,	_
44-102	7928-7931	and	_
44-103	7932-7939	loading	_
44-104	7940-7942	of	_
44-105	7943-7948	first	_
44-106	7949-7958	component	_
44-107	7959-7960	>	_
44-108	7961-7965	0.33	_
44-109	7966-7967	;	_
44-110	7968-7974	sample	_
44-111	7975-7984	excluding	_
44-112	7985-7993	outliers	_
44-113	7994-7995	:	_
44-114	7996-8004	variance	_
44-115	8005-8014	explained	_
44-116	8015-8016	=	_
44-117	8017-8022	60.05	_
44-118	8023-8024	%	_
44-119	8025-8026	,	_
44-120	8027-8032	32.05	_
44-121	8033-8034	%	_
44-122	8035-8038	and	_
44-123	8039-8044	72.05	_
44-124	8045-8046	%	_
44-125	8047-8059	respectively	_
44-126	8060-8063	for	_
44-127	8064-8068	each	_
44-128	8069-8075	subset	_
44-129	8076-8079	and	_
44-130	8080-8087	loading	_
44-131	8088-8090	of	_
44-132	8091-8096	first	_
44-133	8097-8106	component	_
44-134	8107-8108	>	_
44-135	8109-8113	0.27	_
44-136	8114-8115	)	_
44-137	8116-8117	.	_

45-1	8118-8121	For	_
45-2	8122-8131	bilateral	_
45-3	8132-8137	brain	_
45-4	8138-8145	regions	_
45-5	8146-8147	,	_
45-6	8148-8160	associations	_
45-7	8161-8168	between	_
45-8	8169-8172	the	_
45-9	8173-8178	three	_
45-10	8179-8183	PGRS	_
45-11	8184-8187	and	_
45-12	8188-8192	each	_
45-13	8193-8200	imaging	_
45-14	8201-8208	measure	_
45-15	8209-8213	were	_
45-16	8214-8222	examined	_
45-17	8223-8228	using	_
45-18	8229-8230	a	_
45-19	8231-8239	repeated	_
45-20	8240-8247	measure	_
45-21	8248-8254	linear	_
45-22	8255-8268	mixed-effects	_
45-23	8269-8277	analysis	_
45-24	8278-8279	,	_
45-25	8280-8289	modelling	_
45-26	8290-8300	hemisphere	_
45-27	8301-8303	as	_
45-28	8304-8305	a	_
45-29	8306-8312	random	_
45-30	8313-8319	factor	_
45-31	8320-8321	(	_
45-32	8322-8327	where	_
45-33	8328-8331	the	_
45-34	8332-8336	PGRS	_
45-35	8337-8338	*	_
45-36	8339-8349	hemisphere	_
45-37	8350-8361	interaction	_
45-38	8362-8368	itself	_
45-39	8369-8372	was	_
45-40	8373-8378	found	_
45-41	8379-8381	to	_
45-42	8382-8384	be	_
45-43	8385-8400	non-significant	_
45-44	8401-8402	)	_
45-45	8403-8404	.	_

46-1	8405-8408	For	_
46-2	8409-8419	unilateral	_
46-3	8420-8430	structures	_
46-4	8431-8432	(	_
46-5	8433-8436	e.g	_
46-6	8437-8438	.	_

47-1	8439-8444	total	_
47-2	8445-8447	GM	_
47-3	8448-8454	volume	_
47-4	8455-8456	,	_
47-5	8457-8464	forceps	_
47-6	8465-8470	major	_
47-7	8471-8472	,	_
47-8	8473-8480	forceps	_
47-9	8481-8486	minor	_
47-10	8487-8490	and	_
47-11	8491-8497	middle	_
47-12	8498-8508	cerebellar	_
47-13	8509-8517	peduncle	_
47-14	8518-8519	)	_
47-15	8520-8521	,	_
47-16	8522-8525	and	_
47-17	8526-8531	those	_
47-18	8532-8537	where	_
47-19	8538-8543	there	_
47-20	8544-8547	was	_
47-21	8548-8549	a	_
47-22	8550-8561	significant	_
47-23	8562-8573	interaction	_
47-24	8574-8581	between	_
47-25	8582-8586	PGRS	_
47-26	8587-8590	and	_
47-27	8591-8601	hemisphere	_
47-28	8602-8603	,	_
47-29	8604-8616	associations	_
47-30	8617-8621	were	_
47-31	8622-8630	analysed	_
47-32	8631-8633	as	_
47-33	8634-8640	single	_
47-34	8641-8651	structures	_
47-35	8652-8659	without	_
47-36	8660-8668	repeated	_
47-37	8669-8681	measurements	_
47-38	8682-8685	and	_
47-39	8686-8693	without	_
47-40	8694-8704	hemisphere	_
47-41	8705-8707	as	_
47-42	8708-8709	a	_
47-43	8710-8718	separate	_
47-44	8719-8723	term	_
47-45	8724-8726	in	_
47-46	8727-8730	the	_
47-47	8731-8736	model	_
47-48	8737-8738	.	_

48-1	8739-8742	For	_
48-2	8743-8746	all	_
48-3	8747-8753	models	_
48-4	8754-8755	,	_
48-5	8756-8766	additional	_
48-6	8767-8772	fixed	_
48-7	8773-8780	effects	_
48-8	8781-8789	included	_
48-9	8790-8793	age	_
48-10	8794-8795	,	_
48-11	8796-8800	age2	_
48-12	8801-8802	,	_
48-13	8803-8809	gender	_
48-14	8810-8811	,	_
48-15	8812-8820	genotype	_
48-16	8821-8826	batch	_
48-17	8827-8828	,	_
48-18	8829-8837	genotype	_
48-19	8838-8843	array	_
48-20	8844-8847	and	_
48-21	8848-8850	15	_
48-22	8851-8871	ancestry-informative	_
48-23	8872-8875	MDS	_
48-24	8876-8886	components	_
48-25	8887-8888	.	_

49-1	8889-8901	Intracranial	_
49-2	8902-8908	volume	_
49-3	8909-8910	,	_
49-4	8911-8921	calculated	_
49-5	8922-8924	as	_
49-6	8925-8928	the	_
49-7	8929-8932	sum	_
49-8	8933-8935	of	_
49-9	8936-8938	WM	_
49-10	8939-8940	,	_
49-11	8941-8943	GM	_
49-12	8944-8947	and	_
49-13	8948-8959	ventricular	_
49-14	8960-8963	CSF	_
49-15	8964-8965	,	_
49-16	8966-8969	was	_
49-17	8970-8974	also	_
49-18	8975-8983	modelled	_
49-19	8984-8986	as	_
49-20	8987-8988	a	_
49-21	8989-8994	fixed	_
49-22	8995-9001	effect	_
49-23	9002-9004	in	_
49-24	9005-9008	the	_
49-25	9009-9017	analysis	_
49-26	9018-9020	of	_
49-27	9021-9032	subcortical	_
49-28	9033-9040	volumes	_
49-29	9041-9043	in	_
49-30	9044-9049	order	_
49-31	9050-9052	to	_
49-32	9053-9059	adjust	_
49-33	9060-9063	for	_
49-34	9064-9075	differences	_
49-35	9076-9078	in	_
49-36	9079-9086	overall	_
49-37	9087-9092	brain	_
49-38	9093-9097	size	_
49-39	9098-9099	.	_

50-1	9100-9104	PGRS	_
50-2	9105-9108	and	_
50-3	9109-9116	imaging	_
50-4	9117-9125	measures	_
50-5	9126-9130	were	_
50-6	9131-9137	scaled	_
50-7	9138-9140	to	_
50-8	9141-9145	zero	_
50-9	9146-9150	mean	_
50-10	9151-9154	and	_
50-11	9155-9162	unitary	_
50-12	9163-9171	standard	_
50-13	9172-9181	deviation	_
50-14	9182-9183	.	_

51-1	9184-9196	Standardised	_
51-2	9197-9201	Beta	_
51-3	9202-9208	values	_
51-4	9209-9212	are	_
51-5	9213-9221	reported	_
51-6	9222-9232	throughout	_
51-7	9233-9240	results	_
51-8	9241-9242	.	_

52-1	9243-9250	Results	_
52-2	9251-9255	were	_
52-3	9256-9265	corrected	_
52-4	9266-9269	for	_
52-5	9270-9278	multiple	_
52-6	9279-9290	comparisons	_
52-7	9291-9296	using	_
52-8	9297-9298	a	_
52-9	9299-9304	false	_
52-10	9305-9314	discovery	_
52-11	9315-9319	rate	_
52-12	9320-9321	(	_
52-13	9322-9325	FDR	_
52-14	9326-9327	)	_
52-15	9328-9338	correction	_
52-16	9339-9340	.	_

53-1	9341-9351	Nagelkerke	_
53-2	9352-9353	’	_
53-3	9354-9355	s	_
53-4	9356-9358	R2	_
53-5	9359-9362	was	_
53-6	9363-9367	used	_
53-7	9368-9370	to	_
53-8	9371-9379	estimate	_
53-9	9380-9383	the	_
53-10	9384-9394	proportion	_
53-11	9395-9397	of	_
53-12	9398-9407	variation	_
53-13	9408-9417	explained	_
53-14	9418-9420	by	_
53-15	9421-9425	PGRS	_
53-16	9426-9427	.	_

54-1	9428-9436	Post-hoc	_
54-2	9437-9445	positive	_
54-3	9446-9453	control	_
54-4	9454-9462	analyses	_
54-5	9463-9464	,	_
54-6	9465-9469	with	_
54-7	9470-9473	age	_
54-8	9474-9476	as	_
54-9	9477-9479	an	_
54-10	9480-9491	independent	_
54-11	9492-9500	variable	_
54-12	9501-9504	and	_
54-13	9505-9509	each	_
54-14	9510-9512	of	_
54-15	9513-9516	the	_
54-16	9517-9522	brain	_
54-17	9523-9531	measures	_
54-18	9532-9534	as	_
54-19	9535-9544	dependent	_
54-20	9545-9553	variable	_
54-21	9554-9555	,	_
54-22	9556-9560	were	_
54-23	9561-9570	performed	_
54-24	9571-9573	in	_
54-25	9574-9579	order	_
54-26	9580-9582	to	_
54-27	9583-9587	test	_
54-28	9588-9591	the	_
54-29	9592-9603	sensitivity	_
54-30	9604-9606	of	_
54-31	9607-9609	UK	_
54-32	9610-9617	Biobank	_
54-33	9618-9625	imaging	_
54-34	9626-9630	data	_
54-35	9631-9632	,	_
54-36	9633-9635	by	_
54-37	9636-9645	verifying	_
54-38	9646-9650	that	_
54-39	9651-9653	we	_
54-40	9654-9659	could	_
54-41	9660-9669	replicate	_
54-42	9670-9673	the	_
54-43	9674-9680	widely	_
54-44	9681-9689	reported	_
54-45	9690-9698	negative	_
54-46	9699-9711	associations	_
54-47	9712-9719	between	_
54-48	9720-9724	many	_
54-49	9725-9735	structural	_
54-50	9736-9741	brain	_
54-51	9742-9750	measures	_
54-52	9751-9754	and	_
54-53	9755-9758	age	_
54-54	9759-9760	(	_
54-55	9761-9770	including	_
54-56	9771-9776	those	_
54-57	9777-9785	reported	_
54-58	9786-9796	previously	_
54-59	9797-9799	in	_
54-60	9800-9802	an	_
54-61	9803-9814	overlapping	_
54-62	9815-9821	sample	_
54-63	9822-9824	in	_
54-64	9825-9827	UK	_
54-65	9828-9835	Biobank	_
54-66	9836-9837	)	_
54-67	9838-9839	.	_

55-1	9840-9845	Fixed	_
55-2	9846-9853	effects	_
55-3	9854-9862	included	_
55-4	9863-9869	gender	_
55-5	9870-9873	for	_
55-6	9874-9877	all	_
55-7	9878-9888	structures	_
55-8	9889-9890	,	_
55-9	9891-9894	and	_
55-10	9895-9899	side	_
55-11	9900-9902	of	_
55-12	9903-9913	hemisphere	_
55-13	9914-9917	for	_
55-14	9918-9929	lateralized	_
55-15	9930-9940	structures	_
55-16	9941-9945	only	_
55-17	9946-9947	.	_

